RDx Bioscience, CEO settle kickback case for $13M

DOJ building

A New Jersey-based clinical laboratory and its chief executive officer agreed to pay more than $13 million to the Department of Justice (DOJ) to settle illegal kickback allegations.

RDx Bioscience and CEO Eric Leykin engaged in a scheme, between 2017 and 2023, to pay five different types of kickbacks designed to induce referrals for lab testing, the DOJ alleged in its settlement agreement published Wednesday.

Under the agreement, RDx and Leykin will pay approximately $10.3 million to the DOJ and $2.9 million to New Jersey, for portions of alleged false claims made to the state’s Medicaid program.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.